- Datum28.04.2025
- Uhrzeit09:00 - 10:00 Uhr
- Veranstalter
XTB
Stefan Salomon
Moderator
Applied Therapeutics Inc. Aktie
Verkaufen
Kaufen
Applied Therapeutics Inc. Chart
Applied Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
11,51 %
Intraday
19,61 %
1 Woche
-27,49 %
1 Monat
-53,48 %
Seit Jahresbeginn
-90,58 %
1 Jahr
-80,18 %
3 Jahre
-98,94 %
5 Jahre
Passender Service zu Applied Therapeutics Inc.
Webinar zu Applied Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,295-10,624
- Jahrestief / Hoch ($)0,295-0,979
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Applied Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Applied Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
